The Association Between Deep Vein Thrombosis, Pulmonary Embolism, and Janus Kinase Inhibitors: Reporting Status and Signal Detection in the Japanese Adverse Drug Event Report Database
Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet bee...
Saved in:
| Published in | Drugs - Real World Outcomes Vol. 11; no. 3; pp. 369 - 375 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Cham
Springer International Publishing
01.09.2024
Springer Springer Nature B.V Adis, Springer Healthcare |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2199-1154 2198-9788 2198-9788 |
| DOI | 10.1007/s40801-024-00447-w |
Cover
| Abstract | Background
Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted.
Objective
The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE.
Methods
JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and “embolic and thrombotic events, venous” (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection.
Results
Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95–3.25) and 1.27 (0.41–2.13), while those of baricitinib for DVT were 4.37 (2.83–6.73) and 1.90 (0.47–3.33), respectively. ROR signals were detected for JAK inhibitors for PE and “embolic and thrombotic events, venous (SMQ),” overall and for several JAK inhibitors but none for IC.
Conclusions
Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient’s background. |
|---|---|
| AbstractList | Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted.
The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE.
JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and "embolic and thrombotic events, venous" (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection.
Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95-3.25) and 1.27 (0.41-2.13), while those of baricitinib for DVT were 4.37 (2.83-6.73) and 1.90 (0.47-3.33), respectively. ROR signals were detected for JAK inhibitors for PE and "embolic and thrombotic events, venous (SMQ)," overall and for several JAK inhibitors but none for IC.
Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient's background. Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted. Objective The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE. Methods JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and “embolic and thrombotic events, venous” (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection. Results Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95–3.25) and 1.27 (0.41–2.13), while those of baricitinib for DVT were 4.37 (2.83–6.73) and 1.90 (0.47–3.33), respectively. ROR signals were detected for JAK inhibitors for PE and “embolic and thrombotic events, venous (SMQ),” overall and for several JAK inhibitors but none for IC. Conclusions Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient’s background. BackgroundAlthough Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted.ObjectiveThe objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE.MethodsJADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and “embolic and thrombotic events, venous” (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection.ResultsOverall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95–3.25) and 1.27 (0.41–2.13), while those of baricitinib for DVT were 4.37 (2.83–6.73) and 1.90 (0.47–3.33), respectively. ROR signals were detected for JAK inhibitors for PE and “embolic and thrombotic events, venous (SMQ),” overall and for several JAK inhibitors but none for IC.ConclusionsSeveral JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient’s background. Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted. Objective The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE. Methods JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and "embolic and thrombotic events, venous" (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection. Results Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95-3.25) and 1.27 (0.41-2.13), while those of baricitinib for DVT were 4.37 (2.83-6.73) and 1.90 (0.47-3.33), respectively. ROR signals were detected for JAK inhibitors for PE and "embolic and thrombotic events, venous (SMQ)," overall and for several JAK inhibitors but none for IC. Conclusions Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient's background. Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted.BACKGROUNDAlthough Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted.The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE.OBJECTIVEThe objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE.JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and "embolic and thrombotic events, venous" (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection.METHODSJADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and "embolic and thrombotic events, venous" (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection.Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95-3.25) and 1.27 (0.41-2.13), while those of baricitinib for DVT were 4.37 (2.83-6.73) and 1.90 (0.47-3.33), respectively. ROR signals were detected for JAK inhibitors for PE and "embolic and thrombotic events, venous (SMQ)," overall and for several JAK inhibitors but none for IC.RESULTSOverall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95-3.25) and 1.27 (0.41-2.13), while those of baricitinib for DVT were 4.37 (2.83-6.73) and 1.90 (0.47-3.33), respectively. ROR signals were detected for JAK inhibitors for PE and "embolic and thrombotic events, venous (SMQ)," overall and for several JAK inhibitors but none for IC.Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient's background.CONCLUSIONSSeveral JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient's background. Abstract Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted. Objective The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE. Methods JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and “embolic and thrombotic events, venous” (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection. Results Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95–3.25) and 1.27 (0.41–2.13), while those of baricitinib for DVT were 4.37 (2.83–6.73) and 1.90 (0.47–3.33), respectively. ROR signals were detected for JAK inhibitors for PE and “embolic and thrombotic events, venous (SMQ),” overall and for several JAK inhibitors but none for IC. Conclusions Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient’s background. Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated with their use. Moreover, their analysis using the Japanese database of spontaneous adverse drug reaction reports has not yet been conducted. The objective of this study was to analyze the Japanese Adverse Drug Event Report database (JADER) to evaluate the association between JAK inhibitors and DVT and PE. JADER reports from April 2004 to October 2023 were analyzed. A classification of reports for the period covered was performed by drug, and an imbalance analysis was performed with oral JAK inhibitors as the target drug and DVT, PE, and "embolic and thrombotic events, venous" (Standardised MedDRA Query; SMQ) as the target adverse events. Reported odds ratios (ROR) and information components (IC) were calculated for signal detection. Overall, 6631 JAK inhibitor-related adverse events were reported, including 60 and 41 cases of DVT and PE, respectively. The ROR and IC of the JAK inhibitors for DVT were 2.52 (1.95-3.25) and 1.27 (0.41-2.13), while those of baricitinib for DVT were 4.37 (2.83-6.73) and 1.90 (0.47-3.33), respectively. ROR signals were detected for JAK inhibitors for PE and "embolic and thrombotic events, venous (SMQ)," overall and for several JAK inhibitors but none for IC. Several JAK inhibitors are under postmarketing phase vigilance, and the number of reported adverse events is low. However, when administering these drugs, care should be taken to avoid the development of thromboembolism, considering the patient's background. |
| Audience | Academic |
| Author | Watanabe, Machiko Aisu, Sayaka Itagaki, Fumio Ohkura, Naoki Maeshima, Tae |
| Author_xml | – sequence: 1 givenname: Tae orcidid: 0000-0003-2179-9045 surname: Maeshima fullname: Maeshima, Tae email: t-maeshima@pharm.teikyo-u.ac.jp organization: Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Teikyo University – sequence: 2 givenname: Sayaka surname: Aisu fullname: Aisu, Sayaka organization: Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Teikyo University – sequence: 3 givenname: Naoki surname: Ohkura fullname: Ohkura, Naoki organization: Department of Medical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Teikyo University – sequence: 4 givenname: Machiko orcidid: 0000-0003-0291-5514 surname: Watanabe fullname: Watanabe, Machiko organization: Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Teikyo University – sequence: 5 givenname: Fumio orcidid: 0000-0002-2816-6542 surname: Itagaki fullname: Itagaki, Fumio organization: Department of Clinical and Pharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Teikyo University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39031227$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUsFu1DAQjVARLaU_wAFZ4sKhKXYSJzYXtLQFWiqB6Iqr5TiTrKvEXuKkq34Zv8dkd2lphSoURY4mb97zvDfPox3nHUTRS0aPGKXF25BRQVlMkyymNMuKePUk2kuYFLEshNhZf8uYMZ7tRgch2HICpZnIimfRbippypKk2It-zRdAZiF4Y_VgvSMfYFgBOHICsCQ_wDoyX_S-K32w4ZB8G9vOO93fkFMstTZ0h0S7ipxrNwbyxTodgJy5hS3t4PvwjnyHpe8H6xpyOegBMRP60jZOtygxgFmLosqA9zjXS-0AGWbVNfR4nvRjQ06vwQ1bInKiB12iyIvoaa3bAAfbcz-afzydH3-OL75-OjueXcQm58kQlznXhkvBuKxkUiRZJXieVDwzBecAJS1YDrmpGM3SGgxMeEkFSJEx0DTdj842tJXXV2rZ2w5nV15btS74vlEaxzMtKJklQnA0P8c8cgO6lrXmdIpBaqhq5Eo3XKNb6puVbttbQkbVFKrahKowVLUOVa2w6_2mazmWHVQGveh1e-8q9_84u1CNv1aMpTkXBUOGN1uG3v8cIQyqs8FA26LXfgwqpSKRXPKiQOjrB9ArP_aY1YSSMsGX8TtUo3Fu62qPwmYiVTNBhWBUyEn26B8ofCrorMFlri3W7zW8-nvS2xH_LCsCxAZgeh9CD7UydlhvLTLb9nEXkwet_2X9NrCAYNdAf-fGI12_AYAAH5A |
| CitedBy_id | crossref_primary_10_3892_mmr_2024_13397 crossref_primary_10_1007_s40278_024_63469_z |
| Cites_doi | 10.1111/bcp.15361 10.1007/s002280050466 10.1002/pds.1001 10.1016/j.pmedr.2019.01.006 10.1371/journal.pone.0126413 10.1007/s00535-021-01829-5 10.1007/s40264-021-01082-y 10.1001/jamadermatol.2022.3516 10.1136/ard-2022-223050 10.1080/14740338.2023.2223955 10.1253/circj.CJ-17-0579 10.1111/1756-185X.13974 10.1002/sim.4780100409 10.1001/jamadermatol.2023.1300 10.1097/00001721-200103000-00002 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 Springer The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2024 2024 |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 Springer – notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2024 2024 |
| DBID | C6C AAYXX CITATION NPM 3V. 7RV 7WY 7WZ 7X7 7XB 87Z 88C 8C1 8FI 8FJ 8FK 8FL ABUWG AFKRA AZQEC BENPR BEZIV CCPQU COVID DWQXO FRNLG FYUFA F~G GHDGH K60 K6~ K9. KB0 L.- M0C M0S M0T NAPCQ PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQBIZ PQBZA PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM ADTOC UNPAY DOA |
| DOI | 10.1007/s40801-024-00447-w |
| DatabaseName | Springer Nature Open Access Journals CrossRef PubMed ProQuest Central (Corporate) Nursing & Allied Health Database ABI/INFORM Collection ABI/INFORM Global (PDF only) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ABI/INFORM Collection Healthcare Administration Database (Alumni) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ABI/INFORM Collection (Alumni Edition) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Business Premium Collection ProQuest One Community College Coronavirus Research Database ProQuest Central Business Premium Collection (Alumni) Health Research Premium Collection ABI/INFORM Global (Corporate) Health Research Premium Collection (Alumni) ProQuest Business Collection (Alumni Edition) ProQuest Business Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ABI/INFORM Professional Advanced ABI/INFORM Global Health & Medical Collection (Alumni Edition) Healthcare Administration Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Business ProQuest One Business (Alumni) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ : directory of open access journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ABI/INFORM Global (Corporate) ProQuest Business Collection (Alumni Edition) ProQuest One Business ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ABI/INFORM Complete ProQuest Central ABI/INFORM Professional Advanced ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ABI/INFORM Complete (Alumni Edition) Business Premium Collection ABI/INFORM Global ProQuest Public Health ABI/INFORM Global (Alumni Edition) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Health Management Coronavirus Research Database ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Business Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Business (Alumni) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) Business Premium Collection (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature Open Access Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 2198-9788 |
| EndPage | 375 |
| ExternalDocumentID | oai_doaj_org_article_94288597860046ceaf9fa5021999aedf 10.1007/s40801-024-00447-w PMC11365871 A808810891 39031227 10_1007_s40801_024_00447_w |
| Genre | Journal Article |
| GeographicLocations | Japan |
| GeographicLocations_xml | – name: Japan |
| GrantInformation_xml | – fundername: Teikyo University |
| GroupedDBID | 0R~ 4.4 5VS 7RV 7WY 7X7 8C1 8FI 8FJ 8FL AAKKN ABEEZ ABUWG ACACY ACGFS ACULB ADBBV ADINQ ADRAZ AFGXO AFKRA AHBYD AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAPOH BCNDV BENPR BEZIV C24 C6C CCPQU DWQXO EBS EJD EMOBN FRNLG FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR ITC KQ8 M0C M0T M48 M~E NAPCQ OK1 PGMZT PIMPY PQBIZ PQBZA PQQKQ RPM RSV SISQX SOJ UKHRP ~JE AAYXX CITATION PHGZM PHGZT PJZUB PPXIY PUEGO NPM 3V. 7XB 8FK AZQEC COVID K60 K6~ K9. L.- PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c652t-b65ac598159d92724d8562d54c755eeb0716e6cd1043feceb65a908e9841ea03 |
| IEDL.DBID | M48 |
| ISSN | 2199-1154 2198-9788 |
| IngestDate | Fri Oct 03 12:50:32 EDT 2025 Sun Oct 26 05:09:19 EDT 2025 Tue Sep 30 17:09:06 EDT 2025 Thu Oct 02 05:48:12 EDT 2025 Tue Oct 07 07:04:44 EDT 2025 Wed Mar 19 02:07:39 EDT 2025 Mon Oct 20 16:55:33 EDT 2025 Wed Feb 19 02:15:59 EST 2025 Wed Oct 01 01:46:01 EDT 2025 Thu Apr 24 23:02:04 EDT 2025 Fri Feb 21 02:39:20 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c652t-b65ac598159d92724d8562d54c755eeb0716e6cd1043feceb65a908e9841ea03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-2179-9045 0000-0003-0291-5514 0000-0002-2816-6542 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1007/s40801-024-00447-w |
| PMID | 39031227 |
| PQID | 3099209915 |
| PQPubID | 2044343 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_94288597860046ceaf9fa5021999aedf unpaywall_primary_10_1007_s40801_024_00447_w pubmedcentral_primary_oai_pubmedcentral_nih_gov_11365871 proquest_miscellaneous_3082959577 proquest_journals_3099209915 gale_infotracmisc_A808810891 gale_infotracacademiconefile_A808810891 pubmed_primary_39031227 crossref_citationtrail_10_1007_s40801_024_00447_w crossref_primary_10_1007_s40801_024_00447_w springer_journals_10_1007_s40801_024_00447_w |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-09-01 |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: 2024-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Cham |
| PublicationPlace_xml | – name: Cham – name: Switzerland – name: Heidelberg |
| PublicationTitle | Drugs - Real World Outcomes |
| PublicationTitleAbbrev | Drugs - Real World Outcomes |
| PublicationTitleAlternate | Drugs Real World Outcomes |
| PublicationYear | 2024 |
| Publisher | Springer International Publishing Springer Springer Nature B.V Adis, Springer Healthcare |
| Publisher_xml | – name: Springer International Publishing – name: Springer – name: Springer Nature B.V – name: Adis, Springer Healthcare |
| References | ChenTLLeeLLHuangHKChenLYLohCHChiCCAssociation of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysisJAMA Dermatol20221581254126110.1001/jamadermatol.2022.3516360013109403856 MytheenSVargheseAJoyJShajiATomAAInvestigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)Expert Opin Drug Saf20232298599410.1080/14740338.2023.222395537294921 WeberJEpidemiology of adverse reactions to nonsteroidal anti inflammatory drugsAdv Inflam Res.19846171:CAS:528:DyaL2cXkvVGqu70%3D ChenTLHuangWTLohCHHuangHKChiCCRisk of venous thromboembolism among adults with atopic dermatitisJAMA Dermatol202315972072710.1001/jamadermatol.2023.13003725663310233455 DongZYeXChenCWangRLiuDXuXThromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration’s Adverse Event Reporting SystemBr J Clin Pharmacol2022884180419010.1111/bcp.15361354664151:CAS:528:DC%2BB38XhsFagtL3M SetyawanJAzimiNStrandVYarurAFridmanMReporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019Drug Saf20214488989710.1007/s40264-021-01082-y3412032182800371:CAS:528:DC%2BB3MXhsFGhsLrP Eli Lilly Japan. Olumiant® Proper Use Information vol. 2023; 8 Safety of 4720 patients in a specific use-results study for rheumatoid arthritis at 3-year observation (in Japanese) https://medical.lilly.com/jp/answers/194368. Accessed 16 Nov 2023. Nicole TranHKlatskyALLower risk of venous thromboembolism in multiple Asian ethnic groupsPrev Med Rep.20191326826910.1016/j.pmedr.2019.01.0063072366163514261:STN:280:DC%2BB3cjpsVOjuw%3D%3D NakajimaASakaiRInoueEHarigaiMPrevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of JapanInt J Rheum Dis2020231676168410.1111/1756-185X.13974330165741:CAS:528:DC%2BB3MXitV2lu7g%3D MatsudaSAokiKKawamataTKimotsukiTKobayashiTKurikiHBias in spontaneous reporting of adverse drug reactions in JapanPLoS ONE20151010.1371/journal.pone.01264132593322644167131:CAS:528:DC%2BC2MXhslWqtbvI PetriHUrquhartJChanneling bias in the interpretation of drug effectsStat Med19911057758110.1002/sim.478010040920576561:STN:280:DyaK3M3otVWksA%3D%3D FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death20240216. Accessed 2 Oct 2023. MolanderVBowerHFrisellTDelcoigneBDi GiuseppeDAsklingJVenous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritisAnn Rheum Dis20238218919710.1136/ard-2022-223050361507491:CAS:528:DC%2BB3sXmsFyhtLk%3D SuehisaENomuraTKawasakiTKanakuraYFrequency of natural coagulation inhibitor (antithrombin III, protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosisBlood Coagul Fibrinolysis200112959910.1097/00001721-200103000-00002113024831:CAS:528:DC%2BD3MXislyksrc%3D OtaSMatsudaAOgiharaYYamadaNNakamuraMMoriTIncidence, characteristics and management of venous thromboembolism in Japan during 2011Circ J20188255556010.1253/circj.CJ-17-057929070745 AndoKFujiyaMWatanabeKHiraokaSShigaHTanakaSA nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in JapanJ Gastroenterol2021561062107910.1007/s00535-021-01829-5346117408604847 RothmanKJLanesSSacksSTThe reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiol Drug Saf20041351952310.1002/pds.100115317031 BateALindquistMEdwardsIROlssonSOrreRLansnerAA Bayesian neural network method for adverse drug reaction signal generationEur J Clin Pharmacol19985431532110.1007/s00228005046696969561:CAS:528:DyaK1cXktFKlsL4%3D H Petri (447_CR18) 1991; 10 V Molander (447_CR13) 2023; 82 447_CR1 E Suehisa (447_CR7) 2001; 12 447_CR17 J Setyawan (447_CR2) 2021; 44 A Nakajima (447_CR12) 2020; 23 S Mytheen (447_CR4) 2023; 22 A Bate (447_CR9) 1998; 54 S Matsuda (447_CR11) 2015; 10 TL Chen (447_CR15) 2022; 158 S Ota (447_CR5) 2018; 82 K Ando (447_CR16) 2021; 56 Z Dong (447_CR3) 2022; 88 J Weber (447_CR10) 1984; 6 KJ Rothman (447_CR8) 2004; 13 TL Chen (447_CR14) 2023; 159 H Nicole Tran (447_CR6) 2019; 13 |
| References_xml | – reference: DongZYeXChenCWangRLiuDXuXThromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration’s Adverse Event Reporting SystemBr J Clin Pharmacol2022884180419010.1111/bcp.15361354664151:CAS:528:DC%2BB38XhsFagtL3M – reference: MytheenSVargheseAJoyJShajiATomAAInvestigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS)Expert Opin Drug Saf20232298599410.1080/14740338.2023.222395537294921 – reference: PetriHUrquhartJChanneling bias in the interpretation of drug effectsStat Med19911057758110.1002/sim.478010040920576561:STN:280:DyaK3M3otVWksA%3D%3D – reference: Eli Lilly Japan. Olumiant® Proper Use Information vol. 2023; 8 Safety of 4720 patients in a specific use-results study for rheumatoid arthritis at 3-year observation (in Japanese) https://medical.lilly.com/jp/answers/194368. Accessed 16 Nov 2023. – reference: ChenTLHuangWTLohCHHuangHKChiCCRisk of venous thromboembolism among adults with atopic dermatitisJAMA Dermatol202315972072710.1001/jamadermatol.2023.13003725663310233455 – reference: MatsudaSAokiKKawamataTKimotsukiTKobayashiTKurikiHBias in spontaneous reporting of adverse drug reactions in JapanPLoS ONE20151010.1371/journal.pone.01264132593322644167131:CAS:528:DC%2BC2MXhslWqtbvI – reference: FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; 2021. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death20240216. Accessed 2 Oct 2023. – reference: RothmanKJLanesSSacksSTThe reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiol Drug Saf20041351952310.1002/pds.100115317031 – reference: ChenTLLeeLLHuangHKChenLYLohCHChiCCAssociation of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysisJAMA Dermatol20221581254126110.1001/jamadermatol.2022.3516360013109403856 – reference: NakajimaASakaiRInoueEHarigaiMPrevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of JapanInt J Rheum Dis2020231676168410.1111/1756-185X.13974330165741:CAS:528:DC%2BB3MXitV2lu7g%3D – reference: OtaSMatsudaAOgiharaYYamadaNNakamuraMMoriTIncidence, characteristics and management of venous thromboembolism in Japan during 2011Circ J20188255556010.1253/circj.CJ-17-057929070745 – reference: WeberJEpidemiology of adverse reactions to nonsteroidal anti inflammatory drugsAdv Inflam Res.19846171:CAS:528:DyaL2cXkvVGqu70%3D – reference: BateALindquistMEdwardsIROlssonSOrreRLansnerAA Bayesian neural network method for adverse drug reaction signal generationEur J Clin Pharmacol19985431532110.1007/s00228005046696969561:CAS:528:DyaK1cXktFKlsL4%3D – reference: SuehisaENomuraTKawasakiTKanakuraYFrequency of natural coagulation inhibitor (antithrombin III, protein C and protein S) deficiencies in Japanese patients with spontaneous deep vein thrombosisBlood Coagul Fibrinolysis200112959910.1097/00001721-200103000-00002113024831:CAS:528:DC%2BD3MXislyksrc%3D – reference: Nicole TranHKlatskyALLower risk of venous thromboembolism in multiple Asian ethnic groupsPrev Med Rep.20191326826910.1016/j.pmedr.2019.01.0063072366163514261:STN:280:DC%2BB3cjpsVOjuw%3D%3D – reference: SetyawanJAzimiNStrandVYarurAFridmanMReporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010–2019Drug Saf20214488989710.1007/s40264-021-01082-y3412032182800371:CAS:528:DC%2BB3MXhsFGhsLrP – reference: MolanderVBowerHFrisellTDelcoigneBDi GiuseppeDAsklingJVenous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritisAnn Rheum Dis20238218919710.1136/ard-2022-223050361507491:CAS:528:DC%2BB3sXmsFyhtLk%3D – reference: AndoKFujiyaMWatanabeKHiraokaSShigaHTanakaSA nationwide survey concerning the mortality and risk of progressing severity due to arterial and venous thromboembolism in inflammatory bowel disease in JapanJ Gastroenterol2021561062107910.1007/s00535-021-01829-5346117408604847 – volume: 88 start-page: 4180 year: 2022 ident: 447_CR3 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.15361 – volume: 54 start-page: 315 year: 1998 ident: 447_CR9 publication-title: Eur J Clin Pharmacol doi: 10.1007/s002280050466 – volume: 13 start-page: 519 year: 2004 ident: 447_CR8 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1001 – volume: 13 start-page: 268 year: 2019 ident: 447_CR6 publication-title: Prev Med Rep. doi: 10.1016/j.pmedr.2019.01.006 – volume: 10 year: 2015 ident: 447_CR11 publication-title: PLoS ONE doi: 10.1371/journal.pone.0126413 – volume: 56 start-page: 1062 year: 2021 ident: 447_CR16 publication-title: J Gastroenterol doi: 10.1007/s00535-021-01829-5 – volume: 44 start-page: 889 year: 2021 ident: 447_CR2 publication-title: Drug Saf doi: 10.1007/s40264-021-01082-y – volume: 158 start-page: 1254 year: 2022 ident: 447_CR15 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2022.3516 – ident: 447_CR1 – volume: 82 start-page: 189 year: 2023 ident: 447_CR13 publication-title: Ann Rheum Dis doi: 10.1136/ard-2022-223050 – volume: 22 start-page: 985 year: 2023 ident: 447_CR4 publication-title: Expert Opin Drug Saf doi: 10.1080/14740338.2023.2223955 – volume: 82 start-page: 555 year: 2018 ident: 447_CR5 publication-title: Circ J doi: 10.1253/circj.CJ-17-0579 – volume: 23 start-page: 1676 year: 2020 ident: 447_CR12 publication-title: Int J Rheum Dis doi: 10.1111/1756-185X.13974 – ident: 447_CR17 – volume: 10 start-page: 577 year: 1991 ident: 447_CR18 publication-title: Stat Med doi: 10.1002/sim.4780100409 – volume: 159 start-page: 720 year: 2023 ident: 447_CR14 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2023.1300 – volume: 6 start-page: 1 year: 1984 ident: 447_CR10 publication-title: Adv Inflam Res. – volume: 12 start-page: 95 year: 2001 ident: 447_CR7 publication-title: Blood Coagul Fibrinolysis doi: 10.1097/00001721-200103000-00002 |
| SSID | ssib044734847 ssj0001510714 |
| Score | 2.2834435 |
| Snippet | Background
Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events... Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events associated... Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events... BackgroundAlthough Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious adverse events... Abstract Background Although Janus kinase (JAK) inhibitors have expanding indications, deep vein thrombosis (DVT) and pulmonary embolism (PE) are serious... |
| SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 369 |
| SubjectTerms | Analysis Cardiovascular disease Dermatitis Internal Medicine Kinases Medicine Medicine & Public Health Mutual fund industry Patients Pharmacology/Toxicology Pharmacotherapy Pulmonary embolism Pulmonary embolisms Rheumatoid arthritis Risk factors Short Communication Thromboembolism Thrombosis Tofacitinib Venous thrombosis |
| SummonAdditionalLinks | – databaseName: DOAJ : directory of open access journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQXoAD4k1gQUZCy4FGNImd2Nx2aVfLIlAlCtqb5STObqSuW7WJqv4y_h4zTpo2IC0cOFWKH7XjL_OQZ74h5E0s8G6uSHzOdOSzhCe-BK3nJ2woZJ5EuXEkrl--xmff2fkFv9gr9YUxYQ09cPPi3kuwjwVYvSJGVy4zupCF5qCZwLLRJi9Q-sK0e84UIIkxJG1pDeUmXzjATB2sNAcDfeSgaTNoXB4dLAy96pD5eMGZ-OuelnJk_n-K7D2d9Xs8ZXepepfcru1Cb9Z6NtvTW6f3yb3W4KTHzUYfkFvGPiRHk4axejOg010C1mpAj-hkx2W9eUR-QjPdO0J60sR10ZExC_rDlBYmWM6v0_mqhOGTegaw1ssNHcOjWbm6HlBtc3qubb2in0sLOpN-sldlWmKVnw-0sf9hExStXuiDvb-Vl7jkkalcnJil8C9gp8IsILoMzOCqSMPvaFlf0jFGbLYT0ZGuNCrmx2R6Op5-PPPbWg9-FvOw8tOY64xLAdZVLsMkZLkAyyznLEs4NyaF04tNnOXgPUaFyQz2l0NhpGCB0cPoCTmwc2ueEZoXqShiPSyQuJ4FUqAPnHKRcQPW7TDxSLA9WpW1POhYjmOmOgZnBwcFcFAODmrtkXfdmEXDAnJj7xNETNcTGbzdA8C1anGt_oZrj7xFvCmUM7C8TLfpErBJZOxSxwL0QwDIDzxy2OsJ8iHrN28Rq1r5tFIROAaYNB1wj7zumnEkxtxZM6-xjwgllzyBV_a0AXi3pUiCMghDaBE96Pf23G-x5ZVjL8ciQhzcdI8Mtl_Jbl03vdRB9yX9wxk8_x9n8ILcCZ1QwJDCQ3JQLWvzEmzQKn3lxM0vQVN7zw priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Zj9MwELaW7gPwgLgJLMhIaHmg0eZyYiMhtKVdLYuoKiho3yIncbqRuklpG1X9Zfw9ZpyjDUgrnirFE9fHeI545htC3vgc7-bSwGSedE0vYIEpQOuZgWdxkQRuojSI69exf_7Du7hklwdk3OTCYFhlIxO1oE6KGL-Rn7hgymCap80-Ln6ZWDUKb1ebEhqyLq2QfNAQY7fIoYPIWD1yOBiNJ98aDvM8BHOpDegqj9jGDB6sQGcLYSI2TZ1Zo_PrYMDobTueiRefgbnpaC8N8v-vKN_TZX_HWbaXrXfJ7TJfyO1Gzud7-uzsPrlXG6L0tOKcB-RA5Q_J8aRCst726XSXmLXq02M62WFcbx-R39BM97aWDqp4LzpUakF_qiyHDpbFdVSsMnh9Us5h_eRyS0fwaJ6trvtU5gm9kHm5ol-yHHQp_ZxfZVGG1X_e08ovgElQtIaBBqm_ZzMc8lCtdfxYTuFfwH6FXkCkKehBV5eG3-GynNERRnLWHdGhXEtU2I_J9Gw0_XRu1jUgzNhnztqMfCZjJjhYXYlwAsdLOFhsCfPigDGlItg9X_lxAl6lm6pYIb2wuBLcs5W03Ceklxe5ekZokkY89aWVIqC9ZwuOvnHEeMwUWL1WYBC72dowrvHRsUzHPGyRnTU7hMAOoWaHcGOQd-07iwod5EbqAXJMS4nI3vpBsZyFtaAIBfiDHLw87uOni1jJVKSSWcieQqokNchb5LcQ5Q8ML5Z1GgVMEpG8wlMOesOGg2Yb5KhDCXIj7jY3HBvWcmsV7k6ZQV63zfgmxuLlqiiRhjuCCRbAkj2tGLydkitASTgOtPAO63fm3G3JsyuNao7FhRi47wbpN6dkN66bFrXfnqT_2IPnN8_6Bbnj6OOOQYRHpLdeluolWJ3r6FUtSv4Aiqp6Sg priority: 102 providerName: ProQuest – databaseName: Springer Nature Open Access Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdgSHw8IBhfgYGMhMYDjZYvJzZv29ppDA1VoqC9WU7ibJEyt2oaVf3L-Pe4S9K0GWiCp0rx2bXj833k7n4m5EPIMTaXRTYLlG8HEYtsAVrPjgKHizTyU12DuJ5_C09_BGcX7KKFycFamBvx-4MS-qDD6wU2xh4je3mX3AMlFdaB2fB4zTvQ5AfriF9TIexibQ7eLecKYSPqTFsz8_dhe3qphu__U0hvaambGZRdGPUReVCZmVotVVFsaaqTJ-Rxa2LSw4YnnpI72uyS--dtEH2X7I8buOrVgE421VflgO7T8QbIevWM_IJmurV_9KhJ6qJDrWf0p84NDDCfXsfTMofu46oAnlbzFR3BoyIvrwdUmZSeKVOV9GtuQGHSL-Yqj3O84uczbYx_WA9FkxdokPp7fomzH-pFnSRmKPwLGKkwCsgtDSPUV0jD73BeXdIRpmu2A9GhWijUys_J5GQ0OT6124se7CRk3sKOQ6YSJjiYVqnwIi9IOZhlKQuSiDGtY9jIUIdJCq6jn-lEI71wuBY8cLVy_Bdkx0yNfkVomsU8C5WTIWp94AqODnDMeMI0mLZOZBF3vcsyaUHQ8S6OQnbwzTVnSOAMWXOGXFrkU9dn1kCA3Ep9hMzTUSJ8d_0AuFq20kAKcPo4uHI8xO8TiVaZyBRzkFOF0mlmkY_IehKFDEwvUW2tBCwS4brkIQfl4MJpci2y16ME4ZD0m9fMK1vhVEofvAKsmHaZRd53zdgTE-6MnlZIwz3BBIvglb1seL1bki9AE3getPDeKeitud9i8qsauhxvEGLgo1tksD4wm3nd9lIH3aH6hz14_X-jvyEPvVoSYObgHtlZzCv9FkzNRfyuljG_AT-acDE priority: 102 providerName: Springer Nature – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLagewAeuF8CAxkJjQeakSZxYvPW0U5jiKkSHdqeIidxtojOrZpEVflj_D3OSdK0KWgaT63iY9eOz7U-_g4h7zyOZ3OJbzJXOqbrM98UYPVM37W4iH0nViWI67cT7-jUPT5jZzVMDt6F2Tq__5hBHwx4bdfEs0ffXNwmOx4Dv7tDdk5PRv1zrB4HkbMJ4RCvvgsTMWbqGzL_HqRlhUqw_r9V8oZN2s6XbA5N75E7hZ7J5UJOJht26fBBVeAoK-EMMR3l536Rh_vRry2wx5st-SG5X7untF_x0yNyS-nHZG9U4Vsvu3S8vq6VdekeHa2Rr5dPyG9ophsbTg-qLDA6UGpGf6hUwwDz6VU4zVLoPiomIARyvqRDeDRJs6sulTqmx1IXGf2aarCw9Iu-TMMUawJ9olW0AK-Eoo8MNEj9Pb3AKQ9UXmaVaQq_Al4tjAKKTsEIZc1p-BzMiws6xPzOeiA6kLlEM_6UjA-H489HZl0Zwow8Zudm6DEZMcHBF4uF7dtuzMGPi5kb-YwpFYLf5CkviiHWdBIVKaQXFleCuz0lLecZ6eipVi8IjZOQJ560EoS5d4GPMGIOGY-YAl_Y8g3SWzFKENWo6Vi8YxI0eM_ldgWwXUG5XcHCIB-aPrMKM-Ra6gPkv4YS8b7LB8ATQa0-AgFRIofYj3v4h0akZCISySxkdiFVnBjkPXJvgFoJphfJ-nIFLBLxvYI-B2vSA_HrGWS3RQnaJGo3r_g_qLVZFjgQRuAV6x4zyNumGXtihp5W0wJpuC2YYD68sueVuDRLcgSYDtuGFt4SpNaa2y06vSyxzrHkEIOg3iDdlcyt53XdS-02cnmDPXj5f-SvyF27FE9MNdwlnXxeqNfgm-bhm1op_QF9IIGA priority: 102 providerName: Unpaywall |
| Title | The Association Between Deep Vein Thrombosis, Pulmonary Embolism, and Janus Kinase Inhibitors: Reporting Status and Signal Detection in the Japanese Adverse Drug Event Report Database |
| URI | https://link.springer.com/article/10.1007/s40801-024-00447-w https://www.ncbi.nlm.nih.gov/pubmed/39031227 https://www.proquest.com/docview/3099209915 https://www.proquest.com/docview/3082959577 https://pubmed.ncbi.nlm.nih.gov/PMC11365871 https://doi.org/10.1007/s40801-024-00447-w https://doaj.org/article/94288597860046ceaf9fa5021999aedf |
| UnpaywallVersion | publishedVersion |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: KQ8 dateStart: 20140101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssib044734847 issn: 2199-1154 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: RPM dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: Health & Medical Collection (Proquest) customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: 7X7 dateStart: 20141201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: BENPR dateStart: 20141201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: 8C1 dateStart: 20141201 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2198-9788 dateEnd: 20250531 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: M48 dateStart: 20141001 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAVX databaseName: Springer Nature Open Access Journals customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: C6C dateStart: 20141201 isFulltext: true titleUrlDefault: http://www.springeropen.com/ providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerOpen customDbUrl: eissn: 2198-9788 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001510714 issn: 2198-9788 databaseCode: C24 dateStart: 20141201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3ZjtMw0NpDguUBcRNYKiOh5YEG5XJiIyHUa7Us2qqCFpWnyEmcbqRuWnqo9IXf4veYydUWVivEi6vGY8fHnLFnhpBXLsezudjTmSNt3fGYpwuQerrnGFxEnh2pLIjrRdc9GzjnQzbcI2W6o2IB59eadphPajAbv_3xff0BCP595QYH_aJRbDk6nk96-mqfHIKkEpjK4WKj7kOV7ZSngrkXsYn-O5h_zhRCx8g0hV_N9d0ekVu2ACqwMAfNlhjLov3_zdO3hNqfFy6rU9c75PYyncr1So7HW4Lt9B65W2iktJGj0H2yp9IH5KSXh7Re12l_46E1r9MT2tsEu14_JL-gmm7tMW3mF79oW6kp_aqSFDqYTa6CyTyB5r3lGPBezta0A4_GyfyqTmUa0XOZLuf0U5KCUKUf08skSDAN0DuaGwgwCYpqMcAg9JdkhENuq0V2kSyl8BZQZKEX4G0KesjSTMNve7Yc0Q5e6Sw6om25kCi5H5H-aaffOtOLZBB66DJroQcukyETHNSvSFie5UQcVLeIOaHHmFIBbKSr3DAC89KOVagQXhhcCe6YShr2Y3KQTlL1lNAoDnjsSiPGyPaOKTgayQHjIVOg_hqeRsxya_2wCJSO-TrGfhXiOcMMHzDDzzDDX2nkTdVmmocJuRG6iRhTQWKI7-zBZDbyC47hCzAMOZh73MVvGKGSsYglMxBThVRRrJHXiG8-kgYML5SFPwVMEkN6-Q0OAsQEijM1crwDCQwk3K0uMdYv6c-3wXJAr2qTaeRlVY0t8VJeqiZLhOGWYIJ5sGRPcgSvplTSiUb4DurvzHm3Jk0us_DmmGWIgR2vkXpJJZtx3bSo9YqS_mEPnv3_wJ6TIyvjCnjT8JgcLGZL9QJU00VQI_ve0IOSt8waOWx2ur3P8K9lOVi6rVr2yaeWcSUsf3YAatDtNb79BoOdjV8 |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbG9jB4QNwpDDASjAca0SR2YiNNaKWdtnWbKujQ3iwncbpIXVp6UdVfxhP_jXNyawtSxcueKsUnri-fzyU-F0LeeQLv5mLf4ky7FvO5b0mQepbPGkJGvhuZLInr-YV3fMlOr_jVFvldxsKgW2XJEzNGHQ1D_Eb-yQVVBsM8bf5l9NPCqlF4u1qW0NBFaYXoIEsxVgR2dMxiDibc5OCkBfv93nGO2r2vx1ZRZcAKPe5MrcDjOuRSgFyPpOM7LBKgE0SchT7nxgQggz3jhRHYLW5sQoP0siGMFMw2uuFCt3fIDnOZBNtvp9m-6H4rAc0Y5o4p9PU8bNnGgCEseGdLaWEqnCKQJwvng_VB495hFt6z-tZ8TVhmNQX-lRwrovNvt87qbvce2Z2lI72Y68FgRXwePSD3C72XHuZAfUi2TPqI7HfzxNmLOu0t48AmdbpPu8uU2ovH5Bc00xUk0WbuXkZbxozoD5Ok0MF4eBMMJwm83p0NYLv0eEHb8GiQTG7qVKcRPdXpbEI7SQqim56k10mQYLGhzzQ3Q2ASFJVvoEHq70kfh9wy08xdLaXwL6AuQy_AQQ30kBWzht_WeNanbXQcLTqiLT3VqB88Ib3bAMNTsp0OU_Oc0CgOROzpRoz585ktBZriARchN6BkN_wascutVWGRjh2rggxUlUg6g4MCOKgMDmpeIx-rd0Z5MpKN1E1ETEWJicSzB8NxXxV8SUkwPwUYlcLDLyWh0bGMNW8gPKU2UVwjHxBvCtkdDC_URdQGTBITh6lDAWLKhnNt18jeGiWwqXC9uUSsKtjkRC0PdY28rZrxTXT9S81whjTCkVxyH5bsWQ7wakquBJnkONAi1qC_Nuf1ljS5zpKoYy0jLnwYV708JctxbVrUenWS_mMPXmye9Ruye9w7P1NnJxedl-Sukx199F_cI9vT8cy8AoV3Grwu2Aol6pYZ2R9B9rYE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGkLg8IO4UBhgJxgONlptjGwmhjbZaV5gq0aG-WU7idJG6tPSiqr8M8e84J0nTFqSKlz1Vik9cXz6fS3wuhLwNBN7NJdxivvYsnzNuSZB6FvdtIWPuxSZP4vrtPDi98M_6rL9Hfq9iYdCtcsUTc0YdjyL8Rn7kgSqDYZ4OO0pKt4huo_V5_NPCClJ407oqp1FApGOWCzDfpp_aDdjrd67bava-nFplhQErCpg7s8KA6YhJATI9li53_ViAPhAzP-KMGROC_A1MEMVgs3iJiQzSS1sYKXzHaNuDbm-Qm9zzJHoT8n4lyX0fs8aUmnoRsOxgqBCWunOktDAJThnCkwfywcqgWe_6Ft6wcmuxJSbzagL_yowNofm3Q2d1q3uX3J5nY71c6OFwQ3C27pN7pcZLjwuIPiB7JntIDrtFyuxlnfbWEWDTOj2k3XUy7eUj8gua6QaG6EnhWEYbxozpD5Nm0MFkdBWOpim83p0PYXP0ZEmb8GiYTq_qVGcxPdPZfEo7aQZCm7azyzRMsczQR1oYIDAJimo30CD193SAQ26YWe6ollH4F1CUoRfgnQZ6yMtYw29jMh_QJrqMlh3Rhp5p1Awek951QOEJ2c9GmXlGaJyEIgm0nWDmfN-RAo3wkImIGVCvbV4jzmprVVQmYsd6IENVpZDO4aAADiqHg1rUyIfqnXGRhmQn9QkipqLEFOL5g9FkoEqOpCQYngLMSRHgN5LI6EQmmtkIT6lNnNTIe8SbQkYHw4t0Ga8Bk8SUYepYgIBy4EQ7NXKwRQkMKtpuXiFWlQxyqtbHuUbeVM34Jjr9ZWY0RxrhSiYZhyV7WgC8mpInQRq5LrSILehvzXm7JUsv8_TpWMWICQ7jqq9OyXpcuxa1Xp2k_9iD57tn_ZrcAvalvrbPOy_IHTc_-ei4eED2Z5O5eQma7ix8lfMUStQ187A_LAuzng |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFLagewAeuF8CAxkJjQeakSZxYvPW0U5jiKkSHdqeIidxtojOrZpEVflj_D3OSdK0KWgaT63iY9eOz7U-_g4h7zyOZ3OJbzJXOqbrM98UYPVM37W4iH0nViWI67cT7-jUPT5jZzVMDt6F2Tq__5hBHwx4bdfEs0ffXNwmOx4Dv7tDdk5PRv1zrB4HkbMJ4RCvvgsTMWbqGzL_HqRlhUqw_r9V8oZN2s6XbA5N75E7hZ7J5UJOJht26fBBVeAoK-EMMR3l536Rh_vRry2wx5st-SG5X7untF_x0yNyS-nHZG9U4Vsvu3S8vq6VdekeHa2Rr5dPyG9ophsbTg-qLDA6UGpGf6hUwwDz6VU4zVLoPiomIARyvqRDeDRJs6sulTqmx1IXGf2aarCw9Iu-TMMUawJ9olW0AK-Eoo8MNEj9Pb3AKQ9UXmaVaQq_Al4tjAKKTsEIZc1p-BzMiws6xPzOeiA6kLlEM_6UjA-H489HZl0Zwow8Zudm6DEZMcHBF4uF7dtuzMGPi5kb-YwpFYLf5CkviiHWdBIVKaQXFleCuz0lLecZ6eipVi8IjZOQJ560EoS5d4GPMGIOGY-YAl_Y8g3SWzFKENWo6Vi8YxI0eM_ldgWwXUG5XcHCIB-aPrMKM-Ra6gPkv4YS8b7LB8ATQa0-AgFRIofYj3v4h0akZCISySxkdiFVnBjkPXJvgFoJphfJ-nIFLBLxvYI-B2vSA_HrGWS3RQnaJGo3r_g_qLVZFjgQRuAV6x4zyNumGXtihp5W0wJpuC2YYD68sueVuDRLcgSYDtuGFt4SpNaa2y06vSyxzrHkEIOg3iDdlcyt53XdS-02cnmDPXj5f-SvyF27FE9MNdwlnXxeqNfgm-bhm1op_QF9IIGA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Association+Between+Deep+Vein+Thrombosis%2C+Pulmonary+Embolism%2C+and+Janus+Kinase+Inhibitors%3A+Reporting+Status+and+Signal+Detection+in+the+Japanese+Adverse+Drug+Event+Report+Database&rft.jtitle=Drugs+-+real+world+outcomes&rft.au=Maeshima%2C+Tae&rft.au=Aisu%2C+Sayaka&rft.au=Ohkura%2C+Naoki&rft.au=Watanabe%2C+Machiko&rft.date=2024-09-01&rft.issn=2199-1154&rft.volume=11&rft.issue=3&rft.spage=369&rft_id=info:doi/10.1007%2Fs40801-024-00447-w&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2199-1154&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2199-1154&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2199-1154&client=summon |